GMTs (A) and seroconversion prices (B) of neutralizing antibodies in different timepoints after administration from the initial vaccine dosage in the stage II trial
GMTs (A) and seroconversion prices (B) of neutralizing antibodies in different timepoints after administration from the initial vaccine dosage in the stage II trial. adults on the 10, 25 g V-01 two-dose group, and 50 g V-01 one-dose group, respectively. Conclusions: The vaccine applicant V-01 is apparently secure and immunogenic. The primary results support the…